tiprankstipranks
Advertisement
Advertisement

ALLO Stock Latest News

Allogene publishes Phase 1 data in Journal of Clinical Oncology
The FlyAllogene publishes Phase 1 data in Journal of Clinical Oncology
4d ago
ALLO
Citizens biotech analyst holds an analyst/industry conference call
PremiumThe Fly
Citizens biotech analyst holds an analyst/industry conference call
13d ago
ALLO
CLLS
Citizens biotech analysts hold an analyst/industry conference call
PremiumThe Fly
Citizens biotech analysts hold an analyst/industry conference call
17d ago
ALLO
CLLS
Allogene Launches ATM Offering to Bolster Capital Flexibility
PremiumCompany Announcements
Allogene Launches ATM Offering to Bolster Capital Flexibility
27d ago
8K
ALLO
Allogene Therapeutics Names Zachary Roberts as New CEO
PremiumCompany Announcements
Allogene Therapeutics Names Zachary Roberts as New CEO
2M ago
8K
ALLO
Allogene Therapeutics says Zachary Roberts to succeed David Chang as CEO
PremiumThe FlyAllogene Therapeutics says Zachary Roberts to succeed David Chang as CEO
2M ago
ALLO
Allogene Earnings Call Highlights Early CAR-T Momentum
Premium
Company Announcements
Allogene Earnings Call Highlights Early CAR-T Momentum
2M ago
ALLO
Allogene Therapeutics Balances Bold Data With Rising Spend
Premium
Company Announcements
Allogene Therapeutics Balances Bold Data With Rising Spend
2M ago
ALLO
Allogene’s UNIVERSAL Trial Completion: What ALLO-715 Data Could Mean for Investors
PremiumCompany Announcements
Allogene’s UNIVERSAL Trial Completion: What ALLO-715 Data Could Mean for Investors
2M ago
ALLO
Allogene Therapeutics reports Q1 EPS (18c), consensus (18c)
PremiumThe Fly
Allogene Therapeutics reports Q1 EPS (18c), consensus (18c)
2M ago
ALLO
Allogene Highlights ALPHA3 Data and Extended Cash Runway
PremiumCompany Announcements
Allogene Highlights ALPHA3 Data and Extended Cash Runway
2M ago
8K
ALLO
Allogene Therapeutics increases 2026 operating cash expense guidance
PremiumThe Fly
Allogene Therapeutics increases 2026 operating cash expense guidance
2M ago
ALLO
Allogene Therapeutics options imply 10.6% move in share price post-earnings
PremiumThe FlyAllogene Therapeutics options imply 10.6% move in share price post-earnings
2M ago
ALLO
ALLO Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
ALLO Upcoming Earnings Report: What to Expect?
2M ago
ALLO
Allogene Therapeutics expands Phase 2 ALPHA3 trial to South Korea, Australia
Premium
The Fly
Allogene Therapeutics expands Phase 2 ALPHA3 trial to South Korea, Australia
3M ago
ALLO
Allogene Therapeutics price target lowered to $11 from $12 at H.C. Wainwright
PremiumThe Fly
Allogene Therapeutics price target lowered to $11 from $12 at H.C. Wainwright
3M ago
ALLO
Allogene Therapeutics upgraded to Neutral from Underweight at JPMorgan
PremiumThe Fly
Allogene Therapeutics upgraded to Neutral from Underweight at JPMorgan
3M ago
ALLO
Allogene Therapeutics Prices Large Common Stock Offering
PremiumCompany Announcements
Allogene Therapeutics Prices Large Common Stock Offering
3M ago
8K
ALLO
Allogene Therapeutics price target raised to $10 from $6 at Jefferies
PremiumThe Fly
Allogene Therapeutics price target raised to $10 from $6 at Jefferies
3M ago
ALLO
Unusually active option classes on open April 15th
PremiumThe FlyUnusually active option classes on open April 15th
3M ago
AEO
ALLO
Allogene Therapeutics 87.5M share Spot Secondary priced at $2.00
Premium
The Fly
Allogene Therapeutics 87.5M share Spot Secondary priced at $2.00
3M ago
ALLO
Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein
Premium
The Fly
Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein
3M ago
ALLO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >